Fibroblast Growth Factor 23 and Osteoprotegerin in Vascular Calcification among Patients without Advanced Chronic Kidney Disease
Abstract
). Associations were examined using Spearman's ρ, and the discrimination of severe coronary artery calcification (CAC) (Agatston ≥400) was evaluated using a receiver operating characteristic (ROC) curve analysis. Results CAC was correlated with FGF-23 (ρ=0.379, p=0.002), but not with fetuin-A or OPG. FGF-23 was also associated with the aortic arch (ρ=0.284, p=0.019), abdominal aortic calcification (ρ=0.311, p=0.010), and left ventricular mass index (ρ=0.425, p<0.001). For severe CAC, OPG showed the highest, albeit modest, discrimination (area under the ROC curve 0.69, 95% confidence interval 0.56-0.82; Youden cutoff 9.47), but it was not independently associated after adjusting for age. All biomarkers showed a weak association with aortic valve calcification. Conclusion In patients without advanced CKD, FGF-23 is associated with systemic vascular calcification and left ventricular remodeling, whereas OPG provides only a modest unadjusted discrimination for severe CAC and does not add to age. These findings suggest a limited, context-dependent role for these biomarkers, and underscore the need for larger, externally validated studies.
Related
- Progress on the related mechanisms of vascular calcification in autogenous arteriovenous fistula in hemodialysis patients
- Uric acid-to-high-density lipoprotein cholesterol ratio and incident vascular calcification in patients with type 2 diabetes mellitus: a retrospective cohort study
- Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
- TMEM174 deficiency reduces longevity by promoting phosphate-driven vascular calcification
- Nutritional Modulation of the Immuno–Biomineral Interface: From Vascular Calcification to a Hypothesis-Generating Framework for Tumor-Associated Biomineralization
BibTeX
@article{senda2026fibroblast,
title = {{Fibroblast Growth Factor 23 and Osteoprotegerin in Vascular Calcification among Patients without Advanced Chronic Kidney Disease}},
author = {Keisuke Senda and Nami Teraoka and Kazuma Masuda and Minami Inoue and Keisuke Machida and Katsuyuki Aizawa and Takahiro Takeuchi and Satoshi Yasukochi and Koichiro Kuwahara},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.6389-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6389-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Fibroblast Growth Factor 23 and Osteoprotegerin in Vascular Calcification among Patients without Advanced Chronic Kidney Disease
AU - Keisuke Senda
AU - Nami Teraoka
AU - Kazuma Masuda
AU - Minami Inoue
AU - Keisuke Machida
AU - Katsuyuki Aizawa
AU - Takahiro Takeuchi
AU - Satoshi Yasukochi
AU - Koichiro Kuwahara
PY - 2026
DA - 2026/07/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6389-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6389-25/_article
AB - ). Associations were examined using Spearman's ρ, and the discrimination of severe coronary artery calcification (CAC) (Agatston ≥400) was evaluated using a receiver operating characteristic (ROC) curve analysis. Results CAC was correlated with FGF-23 (ρ=0.379, p=0.002), but not with fetuin-A or OPG. FGF-23 was also associated with the aortic arch (ρ=0.284, p=0.019), abdominal aortic calcification (ρ=0.311, p=0.010), and left ventricular mass index (ρ=0.425, p<0.001). For severe CAC, OPG showed the highest, albeit modest, discrimination (area under the ROC curve 0.69, 95% confidence interval 0.56-0.82; Youden cutoff 9.47), but it was not independently associated after adjusting for age. All biomarkers showed a weak association with aortic valve calcification. Conclusion In patients without advanced CKD, FGF-23 is associated with systemic vascular calcification and left ventricular remodeling, whereas OPG provides only a modest unadjusted discrimination for severe CAC and does not add to age. These findings suggest a limited, context-dependent role for these biomarkers, and underscore the need for larger, externally validated studies.
SN - 1349-7235
SN - 0918-2918
ER -